HDL scavenger receptor class B type i and platelet function

Current Opinion in Lipidology

Volumn 22, Issue 4, 2011, Pages 277-282

  Nofer, Jerzy Roch ^a,b   Van Eck, Miranda ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

CD36; HDL; platelets; scavenger receptor class B type I

Indexed keywords

FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIGAND; SCAVENGER RECEPTOR BI;

ANTICOAGULATION; ARTERY THROMBOSIS; BONE MARROW TRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; LIPID OXIDATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; VEIN THROMBOSIS; WILD TYPE;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; HUMANS; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; PLATELET ACTIVATION; SCAVENGER RECEPTORS, CLASS B;

ANIMALIA; MURINAE; MUS;

EID: 79960644582     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834701de     Document Type: Review

References (35)

1. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol 2009; 103 (3 Suppl):4A-10A.
2. Nofer JR, Brodde MF, Kehrel BE. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 2010; 37:726-735.
3. Von Hundelshausen P, Koenen RR, Weber C. Platelet-mediated enhancement of leukocyte adhesion. Microcirculation 2009; 16:84-96.
4. Siegel-Axel D, Daub K, Seizer P, et al. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. Cardiovasc Res 2008; 78:8-17. (Pubitemid 351430965)
5. Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99:480-486. (Pubitemid 351549284)
6. Escola-Gil JC, Calpe-Berdiel L, Palomer X, et al. Antiatherogenic role of highdensity lipoproteins: insights from genetically engineered-mice. Front Biosci 2006; 11:1328-1348. (Pubitemid 43253426)
7. Di Angelantonio E, Sarwar N, Perry P, et al., Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
8. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117:93-102. (Pubitemid 350301144)
9. Korporaal SJ, Akkerman JW. Platelet activation by low density lipoprotein and high density lipoprotein. Pathophysiol Haemost Thromb 2006; 35:270-280. (Pubitemid 44155945)
10. HoekstraM, Van Berkel TJ, Van EckM. Scavenger receptor BI: a multipurpose player in cholesterol and steroid metabolism. World J Gastroenterol 2010; 16:5916-5924.
11. Dole VS, Matuskova J, Vasile E, et al. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2008; 28:1111-1116.
12. Holm TM, Braun A, Trigatti BL, et al. Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. Blood 2002; 99:1817-1824. (Pubitemid 34533058)
13. Meurs I, Hoekstra M, van Wanrooij EJ, et al. HDL cholesterol levels are an important factor for determining the lifespan of erythrocytes. Exp Hematol 2005; 33:1309-1319. (Pubitemid 41540519)
14. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem 2003; 278:23699-23705. (Pubitemid 36830193)
15. Imachi H, Murao K, Cao W, et al. Expression of human scavenger receptor B1 on and in human platelets. Arterioscler Thromb Vasc Biol 2003; 23:898-904. (Pubitemid 36566184)
16. Ma Y, Ashraf MZ, Podrez EA. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. Blood 2010; 116:1932-1941.
17. Korporaal SJ, Meurs I, Hauer AD, et al. Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol. Arterioscler Thromb Vasc Biol 2011; 31:34-42.
18. Shattil SJ, Anaya-Galindo R, Bennett J, et al. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55:636-643.
19. Sinzinger H, Pirich C, Bednar J, O'Grady J. Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis. Thromb Res 1996; 82:291-301. (Pubitemid 26180348)
20. Ferroni P, Basili S, Santilli F, Dav̀ G. Low-density lipoprotein-lowering medication and platelet function. Pathophysiol Haemost Thromb 2006; 35:346-354. (Pubitemid 44155951)
21. Vergeer M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364:136-145.
22. Ritsch A, Sonderegger G, Sandhofer A, et al. Scavenger receptor class B type I polymorphisms and peripheral arterial disease. Metabolism 2007; 56:1135-1141. (Pubitemid 47028576)
23. Koller E, Koller F, Binder BR. Purification and identification of the lipoproteinbinding proteins from human blood platelet membrane. J Biol Chem 1989; 264:12412-12418. (Pubitemid 19191132)
24. Brodde MF, Korporaal SJ, Herminghaus G, et al. Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI Role of negatively charged phospholipids. Atherosclerosis 2011; 215:374-382.
25. Rigotti A, Acton SL, Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995; 270:16221-16224.
26. Valiyaveettil M, Kar N, Ashraf MZ, et al. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 2008; 111:1962-1971. (Pubitemid 351451506)
27. Takahashi Y, Chiba H, Matsuno K, et al. Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Biochem Biophys Res Commun 1996; 222:453-459. (Pubitemid 26335037)
28. Assinger A, Schmid W, Eder S, et al. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett 2008; 582:778-784.
29. Assinger A, Koller F, Schmid W, et al. Hypochlorite-oxidized LDL induces intraplatelet ROS formation and surface exposure of CD40L: a prominent role of CD36. Atherosclerosis 2010; 213:129-134.
30. Smith JD. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs 2010; 11:989-996.
31. Spieker LE, Sudano I, Hü rlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105:1399-1402. (Pubitemid 34263266)
32. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119:2103-2111.
33. Lerch PG, Spycher MO, Doran JE. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost 1998; 80:316-320. (Pubitemid 28393630)
34. Pajkrt D, Lerch PG, van der Poll T, et al. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost 1997; 77:303-307. (Pubitemid 27084920)
35. Calkin C, Drew G, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120:2095-2104.